D.E. Shaw & Co’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1M | Buy |
40,542
+29,762
| +276% | +$709K | ﹤0.01% | 3444 |
|
|
2025
Q4 | $252K | Sell |
10,780
-94,341
| -90% | -$2.1M | ﹤0.01% | 4233 |
|
|
2025
Q3 | $2.07M | Buy |
105,121
+31,149
| +42% | +$641K | ﹤0.01% | 2958 |
|
|
2025
Q2 | $1.61M | Sell |
73,972
-26,423
| -26% | -$624K | ﹤0.01% | 2906 |
|
|
2025
Q1 | $2.43M | Buy |
100,395
+82,222
| +452% | +$1.85M | ﹤0.01% | 2464 |
|
|
2024
Q4 | $379K | Buy |
+18,173
| New | +$390K | ﹤0.01% | 3774 |
|
|
2024
Q2 | – | Sell |
-12,261
| Closed | -$195K | – | 4535 |
|
|
2024
Q1 | $195K | Sell |
12,261
-38,658
| -76% | -$583K | ﹤0.01% | 3927 |
|
|
2023
Q4 | $856K | Sell |
50,919
-101,149
| -67% | -$1.38M | ﹤0.01% | 3238 |
|
|
2023
Q3 | $1.78M | Sell |
152,068
-223,550
| -60% | -$2.99M | ﹤0.01% | 2671 |
|
|
2023
Q2 | $5.05M | Sell |
375,618
-803,804
| -68% | -$11.6M | 0.01% | 1848 |
|
|
2023
Q1 | $19.6M | Sell |
1,179,422
-444,544
| -27% | -$7.33M | 0.02% | 909 |
|
|
2022
Q4 | $30.2M | Sell |
1,623,966
-241,059
| -13% | -$3.71M | 0.03% | 671 |
|
|
2022
Q3 | $23.9M | Buy |
1,865,025
+437,975
| +31% | +$5.19M | 0.03% | 745 |
|
|
2022
Q2 | $10M | Buy |
1,427,050
+385,083
| +37% | +$2.82M | 0.01% | 1390 |
|
|
2022
Q1 | $8.64M | Buy |
1,041,967
+470,180
| +82% | +$3.32M | 0.01% | 1733 |
|
|
2021
Q4 | $3.87M | Buy |
571,787
+166,929
| +41% | +$1.1M | ﹤0.01% | 2667 |
|
|
2021
Q3 | $2.15M | Sell |
404,858
-47,480
| -10% | -$260K | ﹤0.01% | 2975 |
|
|
2021
Q2 | $2.6M | Buy |
452,338
+301,946
| +201% | +$1.56M | ﹤0.01% | 2670 |
|
|
2021
Q1 | $693K | Sell |
150,392
-206,555
| -58% | -$821K | ﹤0.01% | 3344 |
|
|
2020
Q4 | $1.19M | Sell |
356,947
-98,857
| -22% | -$332K | ﹤0.01% | 2909 |
|
|
2020
Q3 | $1.35M | Sell |
455,804
-262,230
| -37% | -$1.03M | ﹤0.01% | 2659 |
|
|
2020
Q2 | $3.32M | Sell |
718,034
-116,563
| -14% | -$524K | ﹤0.01% | 2000 |
|
|
2020
Q1 | $3.21M | Buy |
834,597
+230,162
| +38% | +$945K | 0.01% | 1801 |
|
|
2019
Q4 | $2.27M | Buy |
+604,435
| New | +$2.83M | ﹤0.01% | 2365 |
|
|
2018
Q4 | – | Sell |
-32,694
| Closed | -$124K | – | 3786 |
|
|
2018
Q3 | $124K | Sell |
32,694
-23,428
| -42% | -$73.4K | ﹤0.01% | 3602 |
|
|
2018
Q2 | $175K | Sell |
56,122
-52,826
| -48% | -$160K | ﹤0.01% | 3574 |
|
|
2018
Q1 | $260K | Buy |
108,948
+3,800
| +4% | +$12.6K | ﹤0.01% | 3215 |
|
|
2017
Q4 | $411K | Buy |
+105,148
| New | +$347K | ﹤0.01% | 3090 |
|
|
2017
Q1 | – | Sell |
-12,651
| Closed | -$13K | – | 3331 |
|
|
2016
Q4 | $13K | Buy |
+12,651
| New | +$14.5K | ﹤0.01% | 3401 |
|
|
2016
Q3 | – | Sell |
-33,094
| Closed | -$23K | – | 3387 |
|
|
2016
Q2 | $23K | Sell |
33,094
-415,239
| -93% | -$334K | ﹤0.01% | 3305 |
|
|
2016
Q1 | $525K | Buy |
448,333
+131,868
| +42% | +$205K | ﹤0.01% | 2759 |
|
|
2015
Q4 | $775K | Buy |
316,465
+177,620
| +128% | +$509K | ﹤0.01% | 2822 |
|
|
2015
Q3 | $417K | Sell |
138,845
-67,258
| -33% | -$290K | ﹤0.01% | 3173 |
|
|
2015
Q2 | $851K | Buy |
+206,103
| New | +$821K | ﹤0.01% | 2823 |
|
Other funds holding CPRX
VCM
DM
VPM
D.E. Shaw & Co's CPRX Position: Q1 2026 in Review
D.E. Shaw & Co increased its Catalyst Pharmaceutical (CPRX) stake by 276% in Q1 2026, buying an estimated $709K and bringing the position to 40,542 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #3444.
D.E. Shaw & Co first reported a position in CPRX in Q2 2015 and has held it in 34 quarters since. The position peaked at $30.2M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- D.E. Shaw & Co held 40,542 shares of Catalyst Pharmaceutical worth $1M as of Q1 2026.
- D.E. Shaw & Co bought 29,762 Catalyst Pharmaceutical shares in Q1 2026, an estimated $709K.
- Catalyst Pharmaceutical made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3444 holding.
- D.E. Shaw & Co first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 34 quarters since.
- D.E. Shaw & Co's Catalyst Pharmaceutical position peaked at $30.2M in Q4 2022.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.